Please assess the completion status of the following clinical trial:

Trial Title: A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects over 18 years old, inclusive~* Has a known childhood diagnosis of classic CAH due to 21-hydroxylase deficiency based on genetic mutation in CYP21A2 and/or documented elevated 17-OHP and currently treated with HC, HC acetate, prednisone, prednisolone, methylprednisolone (or a combination of the aforementioned GCs)~* Has been on a stable supraphysiologic dose of GC replacement ≥15 mg/day and ≤60 mg/day in HC equivalents~* For subjects with the salt-wasting form of CAH, subject has been on a stable dose of mineralocorticoid replacement for ≥1 month before screening~Exclusion Criteria:~* Has a known or suspected diagnosis of any other known form of classic CAH (not due to 21 hydroxylase deficiency)~* Has a history that includes bilateral adrenalectomy or hypopituitarism~* Has a history of allergy or hypersensitivity to Tildacerfont, any of its excipients, or any other CRF1 receptor antagonist~* Current treatment with dexamethasone as GC therapy for CAH. Prior treatment with dexamethasone is allowed as long as the transition to an alternative GC regimen (eg, HC, prednisone, or prednisolone) has resulted in a stable dose of GC replacement for ≥1 month before screening.~* Shows clinical signs or symptoms of adrenal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tildacerfont Group 1 (Type: EXPERIMENTAL): Tildacerfont administered daily via oral tablet for 12 weeks at dose level 1
- Tildacerfont Group 2 (Type: EXPERIMENTAL): Tildacerfont administered daily via oral tablet for 12 weeks at dose level 2
- Tildacerfont Group 3 (Type: EXPERIMENTAL): Tildacerfont administered daily via oral tablet for 70 weeks at dose level 3
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered daily via oral tablet for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).